ArticleThe Journal of rheumatology2021
Risk of Adverse Outcomes in Hospitalized Patients With Autoimmune Disease and COVID-19: A Matched Cohort Study From New York City.
Article in The Journal of rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- Viral associations in multiple sclerosis: pathogenetic mechanisms and therapeutic implications.Virology journal · 2026Review
- Redefining Healthcare With Artificial Intelligence (AI): The Contributions of ChatGPT, Gemini, and Co-pilot.Cureus · 2024Review
- Article
- Preexisting Autoimmunity Is Associated With Increased Severity of Coronavirus Disease 2019: A Retrospective Cohort Study Using Data From the National COVID Cohort Collaborative (N3C).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Hospitalization, Critical Illness, and Mortality Outcomes of COVID-19 in Patients With Rheumatoid Arthritis.ACR open rheumatology · 2023Article
- Pre-existing autoimmunity is associated with increased severity of COVID-19: A retrospective cohort study using data from the National COVID Cohort Collaborative (N3C).medRxiv : the preprint server for health sciences · 2023Article
- Review
- Interplay of diabetes mellitus and rheumatic diseases amidst the COVID-19 pandemic: influence on the risk of infection, outcomes, and immune responses.Clinical rheumatology · 2022Review
- Risk of Severe COVID-19 Outcomes Among Patients with Immune-Mediated Inflammatory Diseases or Malignancies: A Retrospective Analysis of Real-World Data in the United States.Advances in therapy · 2022Article
- Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: a retrospective, comparative, multicentre cohort study.The Lancet. Rheumatology · 2022Article
- Adverse outcome and severity of COVID-19 in patients with autoimmune bullous diseases: A historical cohort study.Dermatologic therapy · 2022Article
- Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus.Arthritis care & research · 2022Article
- Anti-SARS-CoV-2 immunoglobulin profile in patients with celiac disease living in a high incidence area.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2022Article
- Humoral immune response to COVID-19 infection or vaccination among celiac disease patients.Central-European journal of immunology · 2022Article
- COVID-19 from a rheumatology perspective: bibliometric and altmetric analysis.Rheumatology international · 2021Review
- Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States.Seminars in arthritis and rheumatism · 2021Article
- Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France.Arthritis research & therapy · 2021Article
- Autoimmune diseases are independently associated with COVID-19 severity: Evidence based on adjusted effect estimates.The Journal of infection · 2021Article
- A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center.Journal of autoimmunity · 2021Observational
- Review of the COVID-19 Risk in Multiple Sclerosis.Journal of cellular immunology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 4 institutions in 3 countries.
Funding
Abstract
objectiveTo examine the effect of autoimmune (AI) disease on the composite outcome of intensive care unit (ICU) admission, intubation, or death from COVID-19 in hospitalized patients.
methodsRetrospective cohort study of 186 patients hospitalized with COVID-19 between March 1, 2020, and April 15, 2020 at NewYork-Presbyterian Hospital/Columbia University Irving Medical Center. The cohort included 62 patients with AI disease and 124 age- and sex-matched controls. The primary outcome was a composite of ICU admission, intubation, and death, with secondary outcome as time to in-hospital death. Baseline demographics, comorbidities, medications, vital signs, and laboratory values were collected. Conditional logistic regression and Cox proportional hazards regression were used to assess the association between AI disease and clinical outcomes.
resultsPatients with AI disease were more likely to have at least one comorbidity (87.1% vs 74.2%,
conclusionAmong patients hospitalized with COVID-19, individuals with AI disease did not have an increased risk of a composite outcome of ICU admission, intubation, or death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.